Jewish American Heritage Month

Posted By admin on June 26, 2022

ESOMAR-certified Future Market Insights (FMI) has recently published an exhaustive yet unbiased analysis of theglobalGaucher and Pompe disease ERT marketproviding insights on key growth trends through 2030.

As the global burden of genetic disorders such as Gaucher disease, Fabry disease, Pompe disease and other abnormalities rise, healthcare providers are scrambling to develop potential therapeutic approaches to offset their impacts.

According to the National Gaucher Foundation, one in every 450 people belonging to the Ashkenazi Jewish community suffer from Type-1 Gaucher disease, the most prevalent form, thereby opening up credible growth prospects for the future.

Key Takeaways

Request a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12771

COVID-19 Impact Analysis

As healthcare organization reorient their resources to fight the coronavirus pandemic, the market for Gaucher & Pompe Disease ERT experienced a substantial blip in the initial months, with treatment sessions declining significantly across several countries.

For instance, until July 2020, Spain recorded a 25% decline in enzyme replacement therapy sessions amongst people suffering from Type-1 and Type-3 Gaucher Disease respectively. This largely occurred as a consequence of rescheduling treatments at a later date.In the United States, hospital visits to avail ERT have registered considerable decline for avoiding exposure to COVID-19 patients. As a result, patient self-administration at home have burgeoned. Furthermore, the pandemic has provided an opportunity to undertake research on lysosomal dysfunction and disease pathogenesis which would enhance clinical care.

Competitive Landscape

Prominent players operating in the Gaucher & Pompe Disease ERT landscape include Shire PLC, Ultragenyx Pharmaceuticals Inc., Sigma-Tau Pharmaceuticals Inc., Pfizer Inc., Alexion Pharmaceuticals Inc., Sanofi SA, Merck KGaA, Tadeka Pharmaceuticals, AbbVie Inc. and BioMarin Pharmaceutical Inc. to name a few.

Request a TOC@ https://www.futuremarketinsights.com/toc/rep-gb-12771

Manufacturers rely on introduction of novel technologies to advance effective ERTs for numerous genetic conditions. For instance, in October 2018, the U.S Food & Drug Administration approved Sigma-Tau Pharmaceuticals (Lediant Biosciences) RevcoviTMinjection for treating adenosine deaminase severe combined immune deficiency (ADA-SCID).

Likewise, Sanofi SA markets the CerezymeERTinjections through its Genzyme subsidiary, which offers a long term efficacy to elderly and pediatric patients suffering from Type-1 Gaucher Disease, and is the only known long-term cure for the condition.

More Insights on FMIs Gaucher and Pompe Disease ERT Market Report

Future Market Insights, in its new report, offers an unbiased analysis of the global Gaucher and Pompe Disease ERT market, analyzing historical demand from 2015-2019 and forecast statistics for 2020-2030. The study reveals growth projections on the Gaucher and Pompe Disease ERT Market on the basis of therapeutic condition (Gaucher disease and Pompe disease), route of administration (oral and parenteral) and distribution channel (hospital pharmacies, specialty treatment pharmacies, retail pharmacies and online pharmacies) across seven prominent regions.

Key Segments of Gaucher and Pompe Diseases ERT Industry Survey

Gaucher and Pompe Diseases ERT Market by Therapeutic Condition:

Gaucher and Pompe Diseases ERT Market by Route of Administration:

Ask An expert here @ https://www.futuremarketinsights.com/askus/rep-gb-12771

Gaucher and Pompe Diseases ERT Market by Distribution Channel:

For Read More Related Insights:https://faceblox.mn.co/posts/24492244?utm_source=manualhttps://drujrake.mn.co/posts/24492242?utm_source=manualhttps://domain.tribe.so/post/surgical-instruments-tracking-system-market-trends-size-share-regional-anal62b2ab9f54613e6fe21692e6https://cipmo-system.mn.co/posts/24492238?utm_source=manualAbout FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Unit No: 1602-006JumeirahBay 2Plot No: JLT-PH2-X2AJumeirahLakes TowersDubaiUnited Arab EmiratesFor Sales Enquiries:sales@futuremarketinsights.comFor Media Enquiries:press@futuremarketinsights.comWebsite:https://www.futuremarketinsights.comLinkedIn|Twitter|Blogs

Read the rest here:

Pompe Diseases Enzyme Replacement Therapy (ERT) Market is predicted to increase at a high 7% CAGR ov - PharmiWeb.com

Category: Ashkenazi
Tags: